| SC 13G/A | 2010-02-11 | INGALLS & SNYDER LLC | ANTIGENICS INC /DE/ | 9,723,967 | 10.0% | EDGAR |
| SC 13G/A | 2010-02-11 | INGALLS & SNYDER VALUE PARTNERS L P | ANTIGENICS INC /DE/ | 8,348,967 | 8.5% | EDGAR |
| SC 13G/A | 2010-01-13 | BAM Opportunity Fund, L.P. | ANTIGENICS INC /DE/ | 4,676,400 | 5.0% | EDGAR |
| SC 13G/A | 2009-09-10 | FMR LLC | ANTIGENICS INC /DE/ | 7,466,100 | 7.8% | EDGAR |
| SC 13G/A | 2009-04-28 | BAM Capital, LLC | ANTIGENICS INC /DE/ | 6,305,650 | 9.5% | EDGAR |
| SC 13G/A | 2009-02-17 | Invus Public Equities, LP | ANTIGENICS INC /DE/ | 3,533,333 | 5.3% | EDGAR |
| SC 13G/A | 2009-02-17 | FLETCHER ASSET MANAGEMENT INC | ANTIGENICS INC /DE/ | 6,078,058 | 8.6% | EDGAR |
| SC 13G/A | 2009-02-12 | FGS ADVISORS LLC | ANTIGENICS INC /DE/ | 0 | 0.0% | EDGAR |
| SC 13G/A | 2009-01-23 | INGALLS & SNYDER VALUE PARTNERS L P | ANTIGENICS INC /DE/ | 6,774,038 | 9.3% | EDGAR |
| SC 13G/A | 2009-01-23 | INGALLS & SNYDER LLC | ANTIGENICS INC /DE/ | 7,152,038 | 9.8% | EDGAR |
| SC 13G/A | 2008-05-12 | Invus Public Equities, LP | ANTIGENICS INC /DE/ | 6,866,666 | 11.5% | EDGAR |
| SC 13G | 2008-04-29 | BAM Opportunity Fund, L.P. | ANTIGENICS INC /DE/ | 6,000,000 | 9.4% | EDGAR |
| SC 13G | 2008-02-14 | FLETCHER ASSET MANAGEMENT INC | ANTIGENICS INC /DE/ | 3,634,683 | 7.2% | EDGAR |
| SC 13G/A | 2008-02-13 | INGALLS & SNYDER LLC | ANTIGENICS INC /DE/ | 5,236,500 | 10.0% | EDGAR |
| SC 13G/A | 2008-02-13 | FGS ADVISORS LLC | ANTIGENICS INC /DE/ | 2,512,567 | 5.5% | EDGAR |
| SC 13G | 2008-02-11 | FMR LLC | ANTIGENICS INC /DE/ | 8,000,000 | 12.9% | EDGAR |
| SC 13G/A | 2008-02-08 | INGALLS & SNYDER VALUE PARTNERS L P | ANTIGENICS INC /DE/ | 4,865,500 | 9.3% | EDGAR |
| SC 13D | 2008-01-22 | ARMEN GARO H | ANTIGENICS INC /DE/ | 13,667,101 | 24.2% | EDGAR |
| SC 13G | 2008-01-16 | Invus Public Equities, LP | ANTIGENICS INC /DE/ | 3,533,333 | 6.3% | EDGAR |
| SC 13G | 2007-04-10 | FGS ADVISORS LLC | ANTIGENICS INC /DE/ | 2,319,967 | 5.1% | EDGAR |